# Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

> **NCT01462890** · PHASE3 · COMPLETED · sponsor: **AGO Study Group** · enrollment: 927 (actual)

## Conditions studied

- Genital Diseases, Female
- Ovarian Diseases
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **OTHER:** specialized pathology review (Germany only)

## Key facts

- **NCT ID:** NCT01462890
- **Lead sponsor:** AGO Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12
- **Target enrollment:** 927 (ACTUAL)
- **Last updated:** 2022-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462890, "Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01462890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*